SCHEMBL580833

SCHEMBL580833

Nc1nccc(-c2ccccc2Oc2ccc([N+](=O)[O-])cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.49
ROCK1 Q13464 2/20 0.45
LMNA P02545 3/20 0.44
HTT P42858 2/20 0.44
RAB9A P51151 1/20 0.44
GSK3B P49841 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.42
HSPB1 P04792 2/20 0.41
EIF4A1 P60842 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CDC7 O00311 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
IKBKB O14920 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580394 0.83 NCOA1 (0.54) CLK1GSK3BCDK5CDK5R1MEN1
SCHEMBL28501185 0.83 HSP90AA1 (0.53) CLK1GSK3BCDK5CDK5R1ALDH1A1
SCHEMBL30507528 0.83 HSP90AA1 (0.53) CLK1GSK3BCDK5CDK5R1ALDH1A1
SCHEMBL1264982 0.82 LMNA (0.42) LMNAHTTRAB9ACDK5CDK5R1
SCHEMBL1264960 0.82 PIK3CA (0.48) LMNAHTTRAB9AGSK3BMAPT
SCHEMBL1264807 0.81 IKBKB (0.43) LMNAHTTRAB9AMAPTALDH1A1
SCHEMBL27736350 0.81 HSPB1 (0.44) LMNAHTTRAB9AMAPTALDH1A1
SCHEMBL9087468 0.78 HSPB1 (0.59) LMNAHTTRAB9AMAPTALDH1A1
SCHEMBL4936375 0.76 ROCK1 (0.54) CLK1ROCK1LMNAHTTRAB9A
SCHEMBL30507248 0.74 CDK5 (0.66) CLK1GSK3BCDK5CDK5R1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242961-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2016-01-26 US disclosed
EP-1984353-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2015-12-30 EP disclosed
EP-2418209-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-06-25 EP disclosed
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2014-03-06 US disclosed
EP-2418209-A1 Aurora kinase modulators and method of use Amgen Inc. (US) 2012-02-15 EP disclosed
US-20110263530-A1 Aurora Kinase Modulators and Method of Use AMGEN INC. (US) 2011-10-27 US disclosed
US-8022221-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-09-20 US disclosed
US-7560551-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-07-14 US disclosed
US-20090163501-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-06-25 US disclosed
EP-1984353-A1 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2008-10-29 EP disclosed
US-20070185111-A1 Aurora kinase modulators and method of use AMGEN INC. 2007-08-09 US disclosed
WO-2007087276-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066430-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, AURKB CLK1 202/4885ROCK1 71/4885LMNA 620/4885
US-20070185111-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 CLK1 153/4885ROCK1 85/4885LMNA 637/4885
US-20110263530-A1 Aurora Kinase Modulators and Method of Use AURKC, AURKA, AURKB CLK1 202/4885ROCK1 71/4885LMNA 620/4885
US-20090163501-A1 Aurora kinase modulators and method of use AURKC, AURKA, AURKB CLK1 202/4885ROCK1 71/4885LMNA 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.